Valtecne (VLT) H2 2025 earnings summary

Executive summary

• Consolidated revenues reached €35.7 million, down 3.3% year-over-year from pro-forma 2024 figures.

• Net profit declined 31.0% to €3.3 million, mainly due to higher amortization from the Utilità acquisition.

• Medical business line accounted for 73% of revenue, confirming strategic focus and growth in this segment.

• Board proposes a dividend of €0.10 per share, totaling €0.6 million.

• Net financial position improved to €-1.8 million (cash positive), reflecting strong operating cash generation.

Financial highlights

• Value of production increased 2.0% to €37.3 million compared to 2024 pro-forma.

• EBITDA was €8.1 million, down 4.1% year-over-year; EBITDA margin at 21.7%.

• Adjusted EBITDA was €9.7 million, down 4.4%; margin at 26.0%.

• Shareholders' equity rose 4.8% to €27.1 million.

• Net financial debt improved from €0.5 million to €-1.8 million (cash positive).

Outlook and guidance

• Management expects positive business performance in 2026, with Medical segment benefiting from favorable market trends and global orthopaedic sector growth.

• Industrial segment shows signs of demand recovery, especially in aerospace, but cost volatility remains a concern.

• Revenue growth anticipated, with profitability expected to remain broadly in line with recent years.